On an adjusted basis, Lilly earned $3.34 per share for the quarter, compared with analysts’ estimates of $3.02 per share ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported ...

Healthify is banking on the rise of GLP-1 weight-loss drugs in India, integrating them with lifestyle coaching. The firm ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Modern Family’ alum Eric Stonestreet opened up to PEOPLE about living with type 2 diabetes and being unable to get a grasp on ...

Eric Stonestreet's life changed forever in two major ways. First, he landed his role in "Modern Family," a critically ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...